A key contributor to Celgene's outsize stock performance this year has been investor read-through from management's confidence on hitting near-and long-term financial metrics. Investors should not be surprised to have management be similarly bullish on ...
istock Analyst · 1/8/2014
Biotechnology giant Celgene Corp. said Wednesday that a drug it was testing for a particular type of arthritis failed to reach its goals, but the news seemed to have little effect on the company’s stock price. Instead of falling, Celgene /quotes/zigman ...
Market Watch Commentary · ByRuss Britt · 7/9/2014
As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of ...
GlobeNewswire · 3/31/2015
More from Bing News
To look at Celgene Corp.'s stock chart in recent months is to think that you are back in 2000, when the sky was the limit for biotechnology stocks. The stock price of this Summit, N.J., cancer-treatment developer has jumped nearly 30 percent in the past ...
Pittsburgh Post-Gazette · 4/6/2006
SUMMIT, N.J. (AP) -- Celgene Corp. said Wednesday that its board approved the repurchase of up to $3 billion in company stock. The biotech drugmaker said it has bought back $1.8 billion in stock this year, completing a $2.5 billion repurchase authorization.
Yahoo News · 6/12/2013
The biotechnology company Celgene said yesterday that it would pay $2.9 billion in cash and stock to acquire Pharmion, strengthening Celgene’s cancer drug portfolio and its distribution in Europe. It is one of the first big acquisitions for Celgene ...
New York Times · ByAndrew Pollack · 11/19/2007
June 30 -- Bloomberg's Julie Hyman examines the stocks on the move at the start of today's trade. She speaks on "Market Makers." · 6/30/2015
Celgene said yesterday that its board of directors has authorized the repurchase of up to an additional $2 billion of the company’s common stock. The Summit-based company, which sells the cancer drugs Thalomid and Revlimid, is the state’s largest ...
New Jersey Online · BySusan Todd · 8/18/2011
Ariad Pharmaceuticals (NASDAQ:ARIA): Stifel boosts the stock to Buy from Hold. Blackhawk Network (NASDAQ:HAWK): Shares are now Buy from Neutral at Citigroup. Its amended price objective is $27. Celgene (NASDAQ:CELG): Biotech stock Celgene
Minyanville · ByJustin Sharon · 12/10/2013
(Dow Jones Business News) World stock markets sold off heavily today as high stakes ... surged more than 50 percent in after-hours trading after larger rival Celgene agreed to take a $1 billion stake in the company.
Cleveland Plain Dealer · 6/30/2015


Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia